Discovery of Nanomolar DCAF1 Small Molecule Ligands
- J Med Chem. 2023 Apr 13;66(7):5041-5060. doi: 10.1021/acs.jmedchem.2c02132.
- 1. Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
- 2. Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.
- 3. Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
- 4. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2C1, Canada.
- 5. X-Chem Inc., Waltham, Massachusetts 02453, United States.
- 6. Relay Therapeutics, Cambridge, Massachusetts 02139, United States.
- 7. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario M5S 3M2, Canada.
- 8. Piramal Discovery Solutions, Pharmaceutical Special Economic Zone, Ahmedabad, Gujarat 382213, India.
- 9. Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
- 10. Department of Chemistry, University of Toronto, Toronto, Ontario M5S 3H6, Canada.
DCAF1 is a substrate receptor of two distinct E3 Ligases (CRL4DCAF1 and EDVP), plays a critical physiological role in protein degradation, and is considered a drug target for various cancers. Antagonists of DCAF1 could be used toward the development of therapeutics for cancers and viral treatments. We used the WDR domain of DCAF1 to screen a 114-billion-compound DNA encoded library (DEL) and identified candidate compounds using similarity search and machine learning. This led to the discovery of a compound (Z1391232269) with an SPR KD of 11 μM. Structure-guided hit optimization led to the discovery of OICR-8268 (26e) with an SPR KD of 38 nM and cellular target engagement with EC50 of 10 μM as measured by cellular thermal shift assay (CETSA). OICR-8268 is an excellent tool compound to enable the development of next-generation DCAF1 ligands toward Cancer therapeutics, further investigation of DCAF1 functions in cells, and the development of DCAF1-based PROTACs.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Ligands for E3 LigaseResearch Areas: Cancer
-